Adherium Limited

$ADR #Adherium #Hailie #asthma #COPD #digitalhealth

Adherium has announced new real-world results from the iCARE study, showing a 67% reduction in hospitalisations and 46% reduction in total cost of care for patients using the Hailie® Smartinhaler® platform. Read the ASX release: bit.ly/46QwqFv

$ADR #Adherium #Hailie #inhaler #COPD #asthma #digitalhealth #remotepatientmonitoring #connectedcare

@Adherium has released a sales update highlighting continued commercial momentum behind its Hailie® Smartinhaler® platform and Remote Patient Monitoring (RPM) model. Read the ASX release: bit.ly/4cGfNA1

$ADR #ASX #digitalhealth #medtech #respiratory #innovation #healthcare #remotepatientmonitoring #Hailie

CEO Dawn Bitz recently provided an investor update on Adherium’s accelerating commercial progress, interim data from the landmark iCARE Study, and the recently completed capital raise. Here’s the replay: youtu.be/DRUzspwesKo

$ADR #Adherium #ASX #digitalhealth #connectedcare #capitalraise #invest

Adherium (ASX:ADR) has announced that it has received firm commitments for a total of $6.70 million under the Placement and institutional component of the Accelerated Pro-Rata Non-Renounceable Entitlement Offer (ANREO). Read the ASX announcement: bit.ly/4rmeNFz

$ADR #Adherium #respiratoryhealth #digitalhealth #capitalraise #healthcare

Adherium has today announced a capital raising of up to approximately A$7.52 million through a Placement and a 1-for-1.5 pro-rata accelerated non-renounceable Entitlement Offer. Read the ASX announcement: bit.ly/3OaZXDs

In this investor update, CEO Dawn Bitz outlines Adherium’s progress in respiratory digital health, highlighting momentum in its remote patient monitoring program and continued growth in recurring revenue. Watch the presentation: youtu.be/E-yiPMVHMak

Today @Adherium (ASX: ADR) hosted an investor lunch featuring CEO @DawnBitz and patient advocate Julia Ovens discussing the large opportunity for respiratory health management in Australia and abroad. Learn more about Adherium at: adherium.com

Adherium releases its December 2025 quarterly report, delivering strong growth across shipments, RPM activations and recurring revenue. Read the ASX release: bit.ly/49MUKdk   $ADR #Adherium #Hailie #inhaler #COPD #asthma #growth #resipiratoryhealth

Adherium has exceeded two key commercial milestones for 2025, with shipments now surpassing both its 2,000 Remote Patient Monitoring (RPM) patient target and 4,000 total patient shipment goal. Read the ASX release: bit.ly/44JDF0W CEO Message: youtu.be/LYsW-NiRDXI

$ADR #Adherium #Leadership #DigitalHealth #RPM #Innovation #RespiratoryCare #ASX

Adherium is seeing continued growth in Remote Patient Monitoring (RPM) through Q2 FY26, with quarter-to-date subscription revenue already ahead of last quarter. Read the ASX release: bit.ly/4qvoyAP

$ADR #Adherium#respiratoryhealth #digitalhealth #remotepatientmonitoring #Hailie

Last week, Adherium’s Chief Executive Officer, Dawn Bitz was joined by Dr Bill McCann, CEO of Allergy Partners to discuss the rollout of the Hailie® platform and how this technology is proactively supporting respiratory care. 🔗 Here’s the replay: bit.ly/3Xu3CO4

Join #Adherium CEO Dawn Bitz and Allergy Partners CEO Dr Bill McCann for an investor webinar on Tues 2 Dec at 9am AEDT to discuss the advanced rollout of Hailie® across Allergy Partners clinics. Register here: bit.ly/48gE3F6 $ADR

@Allergy $ADR #respiratoryhealth #healthcare #Hailie

Adherium’s collaboration with @Allergy Partner has reached a milestone with the rollout of Hailie® Smartinhaler sensors and digital monitoring services across almost 70% of the network’s 110 clinics nationwide.  Read the ASX release: bit.ly/44z3qkj